Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Histone deacetylases (HDACs) regulate critical cell functions, including development and cancer.
• HDACs are a large enzyme family with complex regulation, often misregulated in cancer.
• Targeting HDACs with inhibitors is a focus of antitumor therapy, but endogenous regulators are poorly understood.

Purpose of the Study:

• To investigate the role of specific tumor suppressors in regulating HDAC activity.
• To identify endogenous inhibitors of HDACs that counteract HDAC-mediated tumorigenesis.
• To explore the potential of endogenous HDAC inhibitors as targeted antitumor agents.

Main Methods:

• Analysis of gene products involved in HDAC regulation and tumorigenesis.
• Examination of tumor suppressors HIC1, DBC1, Chfr, and REN in relation to HDAC1 and Sirt1.
• Investigation of gene deletion and silencing frequencies in human cancers.

Main Results:

• Tumor suppressors HIC1 and DBC1 repress Sirt1 function.
• Chfr and REN downregulate HDAC1 via ubiquitin-dependent degradation.
• Loss of these tumor suppressors leads to increased HDAC activity and oncogenesis.
• These genes are frequently deleted or silenced in human cancers.

Conclusions:

• Endogenous HDAC inhibitors play a critical role in preventing HDAC-mediated tumorigenesis.
• The identified tumor suppressors act as endogenous inhibitors of HDACs.
• Endogenous HDAC inhibitors represent a promising therapeutic strategy for targeting oncogenic pathways.